Acadia Pharmaceuticals | ACAD - Loan Capital


Acadia Pharmaceuticals reported $0 in Loan Capital for its fiscal quarter ending in March of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
ALKERMES USD 1.48B 1.2B Mar/2026
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Cytokinetics USD 247.21M 868.77M Mar/2026
Eisai JPY 134.78B 12M Mar/2026
Eli Lilly USD 39.37B 1.5B Mar/2026
Incyte USD 29.41M 785K Mar/2026
J&J USD 37.53B 1.91B Mar/2026
Moderna USD 603M 7M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pfizer USD 60.57B 1.08B Mar/2026
Prothena USD 0 0 Dec/2024
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025